EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients
Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, according to results from the COMMAND study reported last week at the EASL International Liver Congress in Amsterdam.
Join the discussion below, or Read more at HIV and Hepatitis.
#1 May 4, 2013
This disease is now cured in most people with this treatment, what a great job by the medical researchers
Add your comments below
|Should state mandate immunizations? New require... (May '11)||Jul 15||BackwoodsBarbie423||9,774|
|Rebuttal over Cochrane Review of DAAs-What is t...||Jul 8||hcvnewdrugs||1|
|Scientific Evidence and the EU Court||Jul 6||VAERS NVICP||1|
|The Liver - Super Foods & Supplements||Jun 30||hcvnewdrugs||1|
|EU court: Vaccines can be blamed for illnesses ...||Jun 21||RIGHT ON||2|
|Burlington dental patients told to get tested f...||Jun '17||Lenny||1|
|The opioid epidemic is making the fight against...||Jun '17||Ronald||2|
Find what you want!
Search Hepatitis Forum Now
Copyright © 2017 Topix LLC